Literature DB >> 8001286

Immunochemical detection of human lactoferrin in feces as a new marker for inflammatory gastrointestinal disorders and colon cancer.

K Uchida1, R Matsuse, S Tomita, K Sugi, O Saitoh, S Ohshiba.   

Abstract

We have developed a new immunochemical test for fecal lactoferrin (LF) utilizing an enzyme-linked immunosorbent assay (ELISA). The ELISA had a sensitivity of about 10 micrograms/L of lactoferrin and the measurable range was 10.0-1000.0 micrograms/L (1.0-100.0 micrograms LF/g feces). The stability of lactoferrin in feces was greater than that of myeloperoxidase and leucocyte elastase. The fecal concentration of lactoferrin (mean +/- SD) in 35 normal subjects was 0.75 +/- 0.83 microgram/g feces, whereas that in 24 patients with colon cancer was 74.4 +/- 88.3 micrograms/g feces. The fecal lactoferrin concentration of 38 patient with active ulcerative colitis was 307.4 +/- 233.9 micrograms/g feces, and that in 36 patients with active Crohn's disease was 191.7 +/- 231.1 micrograms/g feces. The ELISA for human fecal lactoferrin might be useful in the diagnosis of colon disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8001286     DOI: 10.1016/0009-9120(94)90027-2

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  13 in total

Review 1.  The role and utility of faecal markers in inflammatory bowel disease.

Authors:  Frank S Lehmann; Emanuel Burri; Christoph Beglinger
Journal:  Therap Adv Gastroenterol       Date:  2015-01       Impact factor: 4.409

2.  Amoebicidal activity of milk, apo-lactoferrin, sIgA and lysozyme.

Authors:  Nidia León-Sicairos; Fernando López-Soto; Magda Reyes-López; Delfino Godínez-Vargas; Cynthia Ordaz-Pichardo; Mireya de la Garza
Journal:  Clin Med Res       Date:  2006-06

Review 3.  Immunomodulatory effects of lactoferrin.

Authors:  Tania Siqueiros-Cendón; Sigifredo Arévalo-Gallegos; Blanca Flor Iglesias-Figueroa; Isui Abril García-Montoya; José Salazar-Martínez; Quintín Rascón-Cruz
Journal:  Acta Pharmacol Sin       Date:  2014-05       Impact factor: 6.150

4.  Noninvasive Markers of Disease Activity in Inflammatory Bowel Disease.

Authors:  Raluca Vrabie; Sunanda Kane
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-09

5.  To culture or not to culture: fecal lactoferrin screening for inflammatory bacterial diarrhea.

Authors:  S W Choi; C H Park; T M Silva; E I Zaenker; R L Guerrant
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

6.  Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma.

Authors:  Frank Serge Lehmann; Francesca Trapani; Ida Fueglistaler; Luigi Maria Terracciano; Markus von Flüe; Gieri Cathomas; Andreas Zettl; Pascal Benkert; Daniel Oertli; Christoph Beglinger
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

Review 7.  Alarmins link neutrophils and dendritic cells.

Authors:  De Yang; Gonzalo de la Rosa; Poonam Tewary; Joost J Oppenheim
Journal:  Trends Immunol       Date:  2009-08-21       Impact factor: 16.687

8.  Performance characteristics and comparison of two immunochemical and two guaiac fecal occult blood screening tests for colorectal neoplasia.

Authors:  P Rozen; J Knaani; Z Samuel
Journal:  Dig Dis Sci       Date:  1997-10       Impact factor: 3.199

9.  Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis.

Authors:  Jun-Ying Xiang; Qin Ouyang; Guo-Dong Li; Nan-Ping Xiao
Journal:  World J Gastroenterol       Date:  2008-01-07       Impact factor: 5.742

10.  Usefulness of fecal lactoferrin and hemoglobin in diagnosis of colorectal diseases.

Authors:  Ichiro Hirata; Masahiro Hoshimoto; Osamu Saito; Masanobu Kayazawa; Takashi Nishikawa; Mitsuyuki Murano; Ken Toshina; Fang-Yu Wang; Ryoichi Matsuse
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.